Literature DB >> 11035427

Should low-dose aspirin also be a background therapy for all patients with systemic lupus erythematosus (SLE)?

A N Malaviya, M Mourou.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11035427     DOI： 10.1177/096120330000900717

Source DB:  PubMed          Journal:  Lupus        ISSN： 0961-2033            Impact factor:   2.911


× No keyword cloud information.
  2 in total

1.  Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus--results from LUMINA (LIX): a multiethnic US cohort.

Authors:  S Durán-Barragán; G McGwin; L M Vilá; J D Reveille; G S Alarcón
Journal:  Rheumatology (Oxford)       Date:  2008-05-29       Impact factor: 7.580

2.  Recurrent life-threatening thromboembolism and catastrophic antiphospholipid syndrome in a patient despite sufficient oral anticoagulation.

Authors:  W Miesbach; I Scharrer; R A Asherson
Journal:  Clin Rheumatol       Date:  2004-03-20       Impact factor: 2.980
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.